Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment

NCT04292730 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04292730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04292730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
March 15, 2020
Completion date
June 26, 2020
Enrollment
1,113 (actual)
Sites
184

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19